Design, Synthesis, and Structure−Activity Relationships of 1-,3-,8-, and 9-Substituted-9-deazaxanthines at the Human A<sub>2B</sub>Adenosine Receptor
Angelo Carotti(University of Bari Aldo Moro), Bernat Vidal(Universidade de Santiago de Compostela), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Nuría B. Centeno(Universidade de Santiago de Compostela), Ferrán Sanz(Universitat Pompeu Fabra), Marı́a Isabel Loza(Universidade de Santiago de Compostela), Angela Stefanachi(University of Bari Aldo Moro), Eddy Sotelo(Universidade de Santiago de Compostela), Rosa M. Nieto(Universidade da Coruña), Cristina Esteve(Universidade de Santiago de Compostela), Enrique Raviña(Universidade de Santiago de Compostela), Vı́ctor Segarra(Centro de Investigación y Desarrollo), Marı́a Isabel Cadavid(Universidade de Santiago de Compostela)
Cited by 38
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293